Go to:
Logótipo
Você está em: Start > Publications > View > Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Map of Premises
Principal
Publication

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations

Title
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Type
Another Publication in an International Scientific Journal
Year
2021-07-11
Authors
Joana Guimaraes
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Title: VaccinesImported from Authenticus Search for Journal Publications
Vol. 30
Final page: 773
ISSN: 2076-393X
Other information
Authenticus ID: P-00V-7F5
Abstract (EN): Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modifying therapies (DMTs) and their immune reactions is vital to analyze vaccine response dynamics. A systematic review on COVID-19 course and outcomes in patients receiving different DMTs was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Emerging data on SARS-CoV-2 vaccines was used to elaborate recommendations. Data from 4417 patients suggest that MS per se do not portend a higher risk of severe COVID-19. As for the general population, advanced age, comorbidities, and higher disability significantly impact COVID-19 outcomes. Most DMTs have a negligible influence on COVID-19 incidence and outcome, while for those causing severe lymphopenia and hypogammaglobulinemia, such as anti-CD20 therapies, there might be a tendency of increased hospitalization, worse outcomes and a higher risk of re-infection. Blunted immune responses have been reported for many DMTs, with vaccination implications. Clinical evidence does not support an increased risk of MS relapse or vaccination failure, but vaccination timing needs to be individually tailored. For cladribine and alemtuzumab, it is recommended to wait 3-6 months after the last cycle until vaccination. For the general anti-CD20 therapies, vaccination must be deferred toward the end of the cycle and the next dose administered at least 4-6 weeks after completing vaccination. Serological status after vaccination is highly encouraged. Growing clinical evidence and continuous surveillance are extremely important to continue guiding future treatment strategies and vaccination protocols.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 18
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Weight variation before and after surgery in Parkinson's disease: A noradrenergic modulation? (2012)
Another Publication in an International Scientific Journal
Joana Guimaraes; Eduardo Moura; Maria Augusta Vieira Coelho; Carolina Garrett
Pregnancy in multiple sclerosis: A reflection on the importance of individualizing management (2020)
Another Publication in an International Scientific Journal
Joana Guimaraes
Neuropathy diagnosis strategy [Abordagem diagnóstica das neuropatias periféricas] (2008)
Another Publication in an International Scientific Journal
Joana Guimaraes; Silveira, F
Neuropathy diagnosis strategy (2008)
Another Publication in an International Scientific Journal
Joana Guimaraes; Silveira, F

See all (62)

Of the same journal

Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine against Toxoplasma gondii (2023)
Another Publication in an International Scientific Journal
Brito, C; Lourenco, C; Magalhaes, J; Salette Reis; Margarida Borges
Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation (2021)
Another Publication in an International Scientific Journal
Castro, LS; Lobo, GS; Pereira, P; Freire, MG; Neves, MC; Pedro, AQ
Genital Warts in Women Vaccinated against HPV in Childhood: A Systematic Review (2024)
Another Publication in an International Scientific Journal
Malheiro, R; Magalhaes, C; Dias, CC; Rodrigues, AG; Carmen Silva
Protective Effect against Neosporosis Induced by Intranasal Immunization with Neospora caninum Membrane Antigens Plus Carbomer-Based Adjuvant (2022)
Article in International Scientific Journal
Alexandra Correia; Alves, P; Frois Martins, R; Teixeira, L; Manuel Vilanova
Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients (2024)
Article in International Scientific Journal
Almeida, B; Dias, TR; Cruz, P; Sousa-Pimenta, M; Teixeira, AL; Pereira, CE; Costa-Silva, B; Oliveira, J; Rui Medeiros; Dias, F

See all (9)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-24 at 08:35:41 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book